Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
23:49:44 EDT Mon 29 Apr 2024
Enter Symbol
or Name
USA
CA



Q:MTEM - MOLECULAR TEMPLATES INC - https://www.mtem.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
MTEM - Q0.11.49·1.782.01.73+0.010.619.5241021.69  1.75  1.63019.4453  1.4017:46:43Apr 0915 min RT 2¢

Recent Trades - Last 10 of 102
Time ETExPriceChangeVolume
17:46:43Q1.75010.045140
16:00:01Q1.730.02527
16:00:01Q1.730.0253
16:00:01Q1.730.0255
16:00:01Q1.730.0254
16:00:01Q1.730.0251
15:59:55Q1.730.02520
15:59:51Q1.730.01100
15:58:08Q1.71-0.01100
15:58:08Q1.740.0357

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-09 08:11U:MTEMNews ReleaseMolecular Templates Presents Interim Data from MT-6402 Phase I Study in Patients with PD-L1+ Solid Tumors at the 2024 American Association for Cancer Research (AACR) Annual Meeting; Monotherapy Activity in Checkpoint-Experienced Head and Neck Cancer Patie
2024-03-29 08:21U:MTEMNews ReleaseMolecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business Update
2024-03-28 08:11U:MTEMNews ReleaseMolecular Templates Announces $9.5 Million Private Placement Offering and Agreement to Amend Second Tranche of July 2023 Purchase Agreement
2024-03-04 08:11U:MTEMNews ReleaseMolecular Templates, Inc. Provides Interim Update
2024-02-08 17:55U:MTEMNews ReleaseMolecular Templates to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
2023-11-13 16:11U:MTEMNews ReleaseMolecular Templates, Inc. Reports Third Quarter 2023 Financial Results and Business Update
2023-11-02 16:11U:MTEMNews ReleaseMolecular Templates Announces First Patient Dosed in Phase 1 Trial Evaluating MT-8421, a Novel Engineered Toxin Body Targeting CTLA-4, in Advanced Solid Tumors
2023-11-01 16:12U:MTEMNews ReleaseMolecular Templates to Participate in Upcoming Investor Conferences
2023-09-28 16:11U:MTEMNews ReleaseMolecular Templates Announces the Appointment of Dr. Maurizio Voi to the Role of Chief Medical Officer
2023-08-11 11:22U:MTEMNews ReleaseMolecular Templates Announces 1-for-15 Reverse Stock Split
2023-08-10 08:08U:MTEMNews ReleaseMolecular Templates, Inc. Reports Second Quarter 2023 Financial Results and Business Update
2023-08-02 16:11U:MTEMNews ReleaseMolecular Templates Announces Executive Leadership Changes
2023-07-13 08:14U:MTEMNews ReleaseMolecular Templates Announces Up to $40 Million Private Placement Offering
2023-06-16 20:56U:MTEMNews ReleaseMolecular Templates Announces Debt Payoff and Restructuring
2023-06-01 07:57U:MTEMNews ReleaseMolecular Templates Announces the FDA Removal of Partial Clinical Hold in the Phase 1 Clinical Trial for MT-0169 and Focuses on Extramedullary Myeloma
2023-05-26 17:10U:MTEMNews ReleaseMolecular Templates to Present on Phase I Dose Escalation Study of MT-6402 at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
2023-05-15 16:13U:MTEMNews ReleaseMolecular Templates, Inc. Reports First Quarter 2023 Financial Results and Business Update